• Ovid, Angelini Pharma Announce Agreement for OV101 americanpharmaceuticalreview
    July 22, 2020
    Ovid Therapeutics and Angelini Pharma announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries..
  • Ovid, Angelini Pharma Enter Exclusive License Agreement contractpharma
    July 14, 2020
    To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe.
PharmaSources Customer Service